ACXP

Acurx Pharmaceuticals, Inc. (ACXP) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacterial infections. The company's lead product candidate is ibezapolstat, currently in late-stage development for the treatment of Clostridioides difficile infections (CDI). The company has not generated any revenue since inception and relies on equity financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: For the three months ended September 30, 2024, total operating expenses decreased by 9% to $2.82 million compared to $3.11 million in the prior year period. This was driven by a decrease in Research and Development (R&D) expenses ($1.20M vs $1.35M) and General and Administrative (G&A) expenses ($1.62M vs $1.77M).
• Year-to-Date Expenses: For the nine months ended September 30, 2024, total operating expenses increased by 20% to $11.32 million compared to $9.46 million in the prior year. R&D expenses increased by 12% ($4.58M vs $4.10M) primarily due to higher manufacturing costs, while G&A expenses increased by 26% ($6.74M vs $5.36M) due to higher professional and legal fees.
• Financing Activity: The company raised approximately $6.21 million net from its At-the-Market (ATM) offering program during the nine months ended September 30, 2024. In the same period in 2023, the company raised $3.54 million from a registered direct offering.
• Share Count: Weighted average shares outstanding increased from 12.28 million (YTD 2023) to 15.91 million (YTD 2024) due to equity issuances.

Guidance, Outlook, and Risks

• Clinical Progress: The company announced positive Phase 2 clinical trial results for ibezapolstat, showing a 96% clinical cure rate in a pooled analysis. A successful End-of-Phase 2 meeting with the FDA was held in April 2024, confirming readiness for Phase 3 trials. The company is preparing for international Phase 3 trials and has submitted a request for a CMC (Chemistry, Manufacturing, and Controls) meeting with the FDA.
• Liquidity and Going Concern: As of September 30, 2024, the company had $5.76 million in cash. Management states this is not sufficient to meet anticipated cash requirements for at least 12 months from the issuance of the financial statements. The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• Capital Needs: The company plans to seek additional equity financing and grant funding. It has an ATM program with approximately $8.0 million remaining capacity as of September 30, 2024.
• Risks: Key risks include the failure of Phase 3 trials, inability to secure regulatory approval, dependence on third-party manufacturers, and the inability to raise additional capital on acceptable terms. The company also faces risks related to geopolitical conflicts and global economic conditions.

Investor Verification Checklist

• Verify the timeline and budget for the upcoming international Phase 3 clinical trials for ibezapolstat.
• Confirm the status of the FDA CMC meeting and any potential delays in manufacturing scale-up.
• Assess the remaining capacity and utilization rate of the $17.0 million ATM program.
• Review the company's specific plan to address the "substantial doubt" regarding its going concern status and the timeline for the next capital raise.
• Monitor the company's cash burn rate relative to its current cash balance of $5.76 million.